Telomir Pharmaceuticals, Inc. (TELO)
| Market Cap | 79.78M +40.5% |
| Revenue (ttm) | n/a |
| Net Income | -9.22M |
| EPS | -0.28 |
| Shares Out | 68.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,351 |
| Open | 1.170 |
| Previous Close | 1.170 |
| Day's Range | 1.160 - 1.170 |
| 52-Week Range | 0.889 - 2.091 |
| Beta | -0.24 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About TELO
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson’s disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer’s disease and Progeria. The company was formerly known as Metallo The... [Read more]
Financial Performance
Financial StatementsNews
Telomir Pharmaceuticals announces publication of data on Telomir-Zn
Telomir Pharmaceuticals (TELO) announced the peer-reviewed publication of preclinical data demonstrating restoration of insulin sensitivity and significant improvement in glucose homeostasis with Telo...
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
Insulin Resistance Was Normalized Following 14 Days of Treatment, Supporting Restoration of Glucose Metabolism and Insulin Sensitivity and Further Validating Telomir-Zn's Metal-Homeostasis Mechanism A...
Telomir Pharmaceuticals reports peer-reviewed publication of data on Telomir-Zn
Telomir Pharmaceuticals (TELO) announced the peer-reviewed publication of preclinical data showing that Telomir-Zn produced dose-dependent survival improvement across multiple endpoints in a Wilson’s ...
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease
Study Published in Advances in Redox Research Demonstrated Dose-Dependent Survival Improvement, Reduced Hepatic Copper Burden, Improved Liver Biomarkers, and Reduced Tissue Degeneration in a Preclinic...
Telomir announces U.S. FDA cleared IND application for Telomir-Zn
Telomir Pharmaceuticals (TELO) announced that the U.S. Food and Drug Administration, FDA, has cleared the Company’s Investigational New Drug, IND, application for its lead candidate, Telomir-Zn, for t...
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer
Company Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Academic Medical Center. MIAMI, FL / ACCESS Newswire / April 30, 2026 / Telomir Pharmaceuticals, Inc. (N...
Telomir Pharmaceuticals completes acquisition of TELI Pharmaceuticals
Telomir Pharmaceuticals (TELO) announced the successful closing of its previously announced acquisition of TELI Pharmaceuticals. The transaction, which was approved by Telomir’s shareholders at the Co...
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)
Transaction establishes global ownership rights of lead program and includes initial capital funding with additional optional milestone-based capital support aligned with key clinical milestones. MIAM...
Telomir Pharmaceuticals submits IND to FDA for Telomir-1 in TNBC
elomir Pharmaceuticals announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration for its lead candidate, Telomir-1, for the treatment of advanced and...
Telomir Pharmaceuticals submits IND to FDA for Telomir-1 in TNBC
elomir Pharmaceuticals announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration for its lead candidate, Telomir-1, for the treatment of advanced and...
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer
First-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways with preclinical efficacy and a favorable GLP safety profile. MIAMI, FL / ACCESS Newswire / March 31, 2026 / Telomi...
Telomir Pharmaceuticals announces in vitro data on Telomir-1
Telomir Pharmaceuticals (TELO) announced new in vitro data demonstrating that Telomir-1 induces broad tumor cell mortality across biologically distinct subtypes of triple-negative breast cancer. Iron-...
Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models
Iron-rescue experiments confirm tumor cell mortality is mechanistically driven, not nonspecific cytotoxicity. MIAMI, FL / ACCESS Newswire / February 17, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TE...
Telomir Pharmaceuticals reports cellular study results on Telomir-1
Telomir Pharmaceuticals (TELO) announced new cellular study results demonstrating that Telomir-1, in the form of Telomir-Zn, induces a rapid and coordinated intracellular redistribution of zinc and ir...
Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging
Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity-without relying on cyt...
Telomir Pharmaceuticals initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of Telomir Pharmaceuticals (TELO) with a Buy rating and $8 price target
Telomir Pharmaceuticals reports results from efficacy study for Telomir-1
Telomir Pharmaceuticals (TELO) announced results from a completed efficacy study evaluating Telomir-1 in zebrafish tumor xenograft animal models of triple-negative breast cancer. The study was conduct...
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models
In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and cancer cell spread. MIAMI, FLORIDA / ACCESS Newsw...
Telomir Pharmaceuticals reports results from safety studies for Telomir-1
Telomir Pharmaceuticals (TELO) announced results from a comprehensive series of IND-enabling Good Laboratory Practice toxicology and safety pharmacology studies for its lead therapeutic candidate, Tel...
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development
No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL / ACCESS Newswire / December 18, 2025 / Telo...
Telomir Pharmaceuticals announces new preclinical data on Telomir-1
Telomir Pharmaceuticals (TELO) reported new preclinical findings demonstrating that its lead therapeutic candidate, Telomir-1, reduced PSA levels in androgen-responsive human prostate cancer cells. PS...
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells
PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November ...
Telomir Pharmaceuticals announces in vitro data on Telomir-1
Telomir Pharmaceuticals (TELO) announced new in vitro findings showing that its investigational compound Telomir-1 kills aggressive human leukemia cells. In this study, HL60 leukemia cells were treate...
Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells
Findings expand Telomir-1's oncology profile into cancers of the blood, adding to previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. MIAMI, FL /...
Telomir Pharmaceuticals announces new preclinical data on Telomir-1
Telomir Pharmaceuticals (TELO) announced new preclinical findings showing that its lead investigational compound Telomir-1 produced a strong, dose-dependent reduction of intracellular iron in human ke...